S-EtifoxineAlternative Names: (S)-Etifoxine
Latest Information Update: 28 Sep 2016
At a glance
- Originator Anvyl
- Mechanism of Action TSPO protein stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Neuropathic pain
Most Recent Events
- 28 Sep 2016 Anvyl has patent protection for S-etifoxine (before September 2016)
- 28 Sep 2016 Preclinical trials in Neuropathic pain in USA (unspecified route)